16:39 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Viking's VK2809 meets in Phase II for NAFLD

Viking Therapeutics Inc. (NASDAQ:VKTX) reported that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). The company plans to meet with FDA early next year...
21:04 , Sep 18, 2018 |  BC Extra  |  Clinical News

Viking gains on Phase II NAFLD data

Viking Therapeutics Inc. (NASDAQ:VKTX) added $9.07 (87%) to $19.46 on Tuesday after reporting that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease. The move translates...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly...
17:58 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Intercept's Ocaliva improves fibrosis in subgroup of primary biliary cholangitis patients

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported data from a subgroup of 13 primary biliary cholangitis (PBC) patients with liver fibrosis or cirrhosis at baseline and who had paired liver biopsies in the Phase III POISE trial...
13:39 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

CymaBay reports additional Phase II data for seladelpar

CymaBay Therapeutics Inc. (NASDAQ:CBAY) reported additional interim data from a Phase II trial of seladelpar (MBX-8025) to treat primary biliary cholangitis (PBC) in patients who had an inadequate response or intolerance to ursodeoxycholic acid. The...
20:00 , Apr 11, 2018 |  BC Extra  |  Clinical News

CymaBay gains on seladelpar data

CymaBay Therapeutics Inc. (NASDAQ:CBAY) was up $1.37 (11%) to $13.44 on Wednesday after reporting additional interim data from a Phase II trial of seladelpar (MBX-8025) to treat primary biliary cholangitis in patients who had an...
16:34 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under which Pfizer...
21:38 , Mar 9, 2018 |  BC Extra  |  Clinical News

AM-Pharma's Phase II sepsis readout triggers Pfizer's takeout option

AM-Pharma B.V. (Bunnik, the Netherlands) reported mixed data on Friday from the Phase II STOP-AKI trial of recAP to treat sepsis-associated acute kidney injury (AKI). The readout marks the start of an option period under...
20:15 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Boxed warning added to Ocaliva label

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced the addition of a boxed warning to FDA's label of Ocaliva obeticholic acid stating that hepatic decompensation and failure can occur in incorrectly dosed primary biliary cholangitis (PBC) patients with...
22:00 , Feb 1, 2018 |  BC Extra  |  Company News

Ocaliva warning could remove overhang on Intercept shares

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced the addition of a boxed warning to FDA's label of Ocaliva obeticholic acid stating that hepatic decompensation and failure can occur in incorrectly dosed primary biliary cholangitis (PBC) patients with...